COVID-19 疫苗对 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 亚变种引起的重症疾病的有效性 - 2021 年 12 月至 2022 年 3 月瑞典南部的监测结果。 - Suppr

Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden.

Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.

Euro Surveill. 2022 May;27(18). doi: 10.2807/1560-7917.ES.2022.27.18.2200322.

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

我们比较了 2021 年 12 月至 2022 年 3 月期间，当 Omicron BA.1 和 BA.2 是瑞典斯科讷省主导的 SARS-CoV-2 变种时，疫苗对重症 COVID-19 的有效性。在 BA.1 向 BA.2 过渡后，至少接种三剂疫苗的人群中的有效性仍保持在 80%以上，但仅接种两剂疫苗的人群中的估计值显著下降至 54%。感染后预防保护在向 BA.2 过渡后也降低。加强疫苗接种似乎是保持足够保护的必要措施。